Table 2.
Association between circulating Treg levels and clinical characteristics in patients with GEP-NETs
| Characteristic | Treg level (%) | p value | |
|---|---|---|---|
| median | IQR | ||
| Gender | |||
| Female | 8.140 | 7.160–9.930 | 0.4718 |
| Male | 8.420 | 7.353–9.823 | |
| Age | |||
| 0–50 years | 8.470 | 7.450–9.905 | 0.1444 |
| Over 50 years | 8.040 | 7.040–9.870 | |
| Functionality | |||
| No | 8.090 | 7.165–9.600 | 0.0053 |
| Yes | 9.400 | 8.290–12.96 | |
| Primary sites | |||
| Pancreas | 9.405 | 8.115–11.15 | 0.0008 |
| GI tract | 8.020 | 7.020–9.480 | |
| Grade | |||
| G1 | 7.660 | 7.058–8.535 | 0.1293 |
| G2 | 8.300 | 7.240–9.935 | 0.0860 |
| G3 | 9.695 | 7.868–11.71 | 0.0190 |
| Burden of liver metastases | |||
| <25% | 8.250 | 7.103–9.620 | 0.9410 |
| 25–50% | 8.165 | 7.413–9.633 | 0.5460 |
| >50% | 9.070 | 7.310–10.38 | 0.3228 |
| TNM stage | |||
| I/II | 7.390 | 6.703–7.995 | 0.0003 |
| III/IV | 8.460 | 7.450–10.06 | |
| Lymph node metastases, n | |||
| No | 8.015 | 7.148–9.305 | 0.0576 |
| Yes | 8.370 | 7.390–10.74 | |
| Lung metastases, n | |||
| No | 8.250 | 7.165–9.775 | 0.4148 |
| Yes | 8.705 | 7.788–11.36 | |
| Liver metastases, n | |||
| No | 7.310 | 6.195–7.995 | <0.0001 |
| Yes | 8.480 | 7.550–10.07 | |
| Bone metastases, n | |||
| No | 8.195 | 7.288–9.508 | 0.1477 |
| Yes | 9.200 | 7.160–11.11 | |
| Other metastases, n | |||
| No | 8.210 | 7.135–9.645 | 0.1279 |
| Yes | 8.855 | 7.640–11.32 | |
Other metastases include the brain, kidney, ovary, enterocoelia, pelvic cavity, etc.